csirt@kutim:~/threat-intel/cve/CVE-2024-41964

Katalog CVE

CVSS 8.1 · High EPSS 0,48%

Kerentanan Incorrect Authorization pada getkirby kirby. Skor CVSS 3.1 8.1 (High) menurut NVD.

Deskripsi (NVD)

Kirby is a CMS targeting designers and editors. Kirby allows to restrict the permissions of specific user roles. Users of that role can only perform permitted actions. Permissions for creating and deleting languages have already existed and could be configured, but were not enforced by Kirby's frontend or backend code. A permission for updating existing languages has not existed before the patched versions. So disabling the languages.* wildcard permission for a role could not have prohibited updates to existing language definitions. The missing permission checks allowed attackers with Panel access to manipulate the language definitions. The problem has been patched in Kirby 3.6.6.6, Kirby 3.7.5.5, Kirby 3.8.4.4, Kirby 3.9.8.2, Kirby 3.10.1.1, and Kirby 4.3.1. Please update to one of these or a later version to fix the vulnerability. There are no known workarounds for this vulnerability.

Rincian

Terbit di NVD
29 Agustus 2024
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
8.1 (High), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-863: Incorrect Authorization
EPSS (30 hari)
0,48% peluang dieksploitasi; lebih tinggi dari 39,6% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
getkirby kirby Semua versi sebelum 3.6.6.6
getkirby kirby Versi 3.7.0 hingga sebelum 3.7.5.5
getkirby kirby Versi 3.8.0 hingga sebelum 3.8.4.4
getkirby kirby Versi 3.9.0 hingga sebelum 3.9.8.2
getkirby kirby Versi 3.10.0 hingga sebelum 3.10.1.1
getkirby kirby Versi 4.0.0 hingga sebelum 4.3.1

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.